Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.64 |
| ▸ | GABRD | O14764 | 1/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.64 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.64 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.64 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.64 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.64 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.64 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.64 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.64 |
| ▸ | GABRE | P78334 | 1/20 | 0.64 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.64 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.64 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.64 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.64 |
| ▸ | HAT1 | O14929 | 1/20 | 0.58 |
| ▸ | EP300 | Q09472 | 1/20 | 0.58 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.56 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15902100 | 0.88 | ADAM17 (0.67) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15901900 | 0.85 | IGF1R (0.64) | HAT1EP300ADAM17PBRM1CTNNB1 | |
| SCHEMBL15902375 | 0.85 | ADAM17 (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15902412 | 0.83 | TSHR (0.56) | HAT1EP300ADAM17CTNNB1WNT3A | |
| SCHEMBL15901066 | 0.82 | HAT1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15988666 | 0.81 | CTNNB1 (0.78) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31651418 | 0.79 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL22026691 | 0.78 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15902289 | 0.78 | BRPF1 (0.61) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14832836 | 0.78 | LMNA (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-04-07 | — | — | US | disclosed |
| US-11279704-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-22 | — | — | US | disclosed |
| EP-3617192-A1 | VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2020-03-04 | — | — | EP | disclosed |
| US-10550123-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-02-04 | — | — | US | disclosed |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2019-11-07 | — | — | US | disclosed |
| EP-2760831-B1 | VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2019-08-07 | — | — | EP | disclosed |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | GABRP 4368/4885GABRD 4740/4885GABRA1 4617/4885 |
| US-11279704-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | GABRP 4368/4885GABRD 4740/4885GABRA1 4617/4885 |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | GABRP 4368/4885GABRD 4740/4885GABRA1 4617/4885 |
| US-10550123-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | GABRP 4368/4885GABRD 4740/4885GABRA1 4617/4885 |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | GABRP 4368/4885GABRD 4740/4885GABRA1 4617/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | GABRP 4368/4885GABRD 4740/4885GABRA1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.